Meloksikam - instructions for use, analogs, reviews and release forms (tablets and suppositories 7.5 mg and 15 mg, injections in ampoules for intramuscular injection) drugs for the treatment of rheumatoid arthritis in adults, children and pregnancy. Composition

In this article, you can read the instructions for using the drug Meloksikam. There are reviews of the visitors of the site - consumers of this medication, as well as opinions of doctors of specialists on the use of Meloxicam in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Meloxicam in the presence of existing structural analogues.Use for the treatment of rheumatoid arthritis and arthrosis in adults, children, as well as during pregnancy and lactation. Composition of the preparation.

Meloksikam - non-steroidal anti-inflammatory drug (NSAID), has anti-inflammatory, antipyretic, analgesic effect. Refers to the class of oxycomams; a derivative of enolic acid.

The mechanism of action is the inhibition of prostaglandin synthesis as a result of selective suppression of the enzymatic activity of cyclooxygenase-2 (COX2).

With the appointment in high doses, long-term use and individual features of the organism, COX2, the selectivity decreases. Suppresses the synthesis of prostaglandins in the inflammatory region to a greater extent than in the mucous membrane of the stomach or kidneys, which is associated with a relatively selective inhibition of COX2. Less often causes erosive and ulcerative diseases of the gastrointestinal tract (GIT).

Composition

Meloksikam + auxiliary substances.

Pharmacokinetics

Absorption from the digestive tract after ingestion - 89%. Eating does not affect absorption. Concentration in plasma is dose-dependent. Passes through the histogematic barriers, penetrates into the synovial fluid.Concentration in the synovial fluid is 50% of the concentration in the plasma. Metabolism in the liver - to inactive metabolites. It is excreted through the intestine and kidneys (approximately in equal proportions), in unchanged form - 5% of the daily dose (through the intestine).

Indications

• rheumatoid arthritis;
• osteoarthritis;
• ankylosing spondylitis (Bechterew's disease)
• other inflammatory and degenerative diseases of the joints, accompanied by pain syndrome;
• for symptomatic therapy, reducing pain and inflammation at the time of use, the progression of the disease is not affected.

Forms of release

Tablets 7.5 mg and 15 mg.

Candles for rectal administration of 7.5 mg and 15 mg.

Solution for intramuscular injection (injections in ampoules for injection).

Instructions for use and dosage

Inside, with food, in a daily dose of 7.5-15 mg. The maximum daily dose is 15 mg, in patients with severe renal failure, on hemodialysis, 7.5 mg. With little or moderate decrease in kidney function (QC more than 25 ml / min), as well as with cirrhosis in a stable clinical condition, dose adjustment is not required. The initial dose in patients with an increased risk of side effects is 7.5 mg per day.

Side effect

• nausea, vomiting;
• abdominal pain;
• constipation;
• flatulence;
• diarrhea;
• eructation;
• esophagitis;
• gastroduodenal ulcer;
• bleeding from the gastrointestinal tract (including latent);
• stomatitis;
• perforation of the gastrointestinal tract;
• colitis;
• gastritis;
• anemia, leukopenia, thrombocytopenia;
• itching;
• skin rash;
• hives;
• photosensitization;
• bullous eruptions;
• erythema multiforme, including Stevens-Johnson syndrome;
• toxic epidermal necrolysis;
• bronchospasm;
• dizziness;
• headache;
• noise in ears;
• drowsiness;
• confusion of consciousness;
• disorientation;
• emotional lability;
• peripheral edema;
• increased blood pressure;
• palpitation;
• "tides" of blood to the skin of the face;
• interstitial nephritis;
• hematuria;
• conjunctivitis;
• impaired vision, including blurred vision;
• angioedema;
• anaphylactoid / anaphylactic reactions.

Contraindications

• hypersensitivity (including NSAIDs of other groups);
• combination of bronchial asthma, recurrent nasal polyposis and paranasal sinuses and intolerance to acetylsalicylic acid and drugs of pyrazolone series;
• peptic ulcer of the stomach and duodenum (in the phase of exacerbation);
• chronic renal failure in patients not undergoing dialysis (creatinine clearance (CK) less than 30 ml / min);
• active gastrointestinal bleeding;
• progressive kidney disease;
• severe hepatic impairment or active liver disease;
• condition after aortocoronary bypass surgery;
• confirmed hyperkalemia;
• inflammatory bowel disease;
• children's age (up to 12 years);
• pregnancy;
• lactation period.

Application in pregnancy and lactation

Contraindicated in pregnancy, during lactation.

special instructions

In the event of peptic ulcers or gastrointestinal bleeding, the development of side effects from the skin and mucous membranes, the drug should be discarded. In patients with reduced circulating blood volume and reduced glomerular filtration (dehydration, chronic heart failure, cirrhosis, nephrotic syndrome, clinically pronounced kidney disease, diuretics, dehydration after major surgical operations), there may be a clinically pronounced chronic renal failure,which is completely reversible after drug withdrawal (in such patients at the beginning of treatment should monitor daily diuresis and kidney function). With persistent and significant increase in transaminases and changes in other indicators of liver function, the drug should be discontinued and control tests should be carried out.

In patients with an increased risk of side effects, treatment starts with a dose of 7.5 mg. In the terminal stage of chronic renal failure in patients on dialysis, the dose should not exceed 7.5 mg per day. During the period of treatment, care must be taken when driving vehicles and engaging in other potentially hazardous activities requiring increased concentration and speed of psychomotor reactions (with dizziness and drowsiness). To reduce the risk of developing adverse events on the part of the gastrointestinal tract, a minimum effective dose should be used with the minimum possible short course.

Drug Interactions

With simultaneous administration with other non-steroidal anti-inflammatory drugs (NSAIDs), the risk of developing ulcerativegastrointestinal lesions and gastrointestinal bleeding; increases the concentration of lithium ions in plasma when used simultaneously with lithium preparations; reduces the effectiveness of intrauterine contraceptives, antihypertensive drugs; indirect anticoagulants, ticlopidine, heparin, thrombolytics increase the risk of bleeding; Methotrexate enhances myelodepressant effect; diuretics increase the risk of kidney dysfunction; cyclosporine increases nephrotoxicity; colestyramin accelerates excretion. Myelotoxic drugs increase the manifestation of hematotoxicity of the drug.

Analogues of the drug Meloxicam

Structural analogs for the active substance:

• Amelotex;
• Arthrosan;
• Bee-ksikam;
• Lem;
• M-Kam;
• Matarin;
• Medsikam;
• Melbeck;
• Melbek forte;
• Meloks;
• Meloksam;
• Meloksikam DS;
• Meloksikam Pfizer;
• Meloxicam Sandoz;
• Meloksikam SHTADA;
• Meloksikam Prana;
• Meloksikam Teva;
• Meloflam;
• Meloflex Rompharm;
• Mesipol;
• Mixol Aud;
• Mirlocks;
• Movalis;
• Movasin;
• Movix;
• Exen Sanovel.

Similar medicines:

Other medicines: